Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled single and multiple dose study of pitolisant in healthy Japanese adults
jRCT2071210104Phase 1Active, not recruiting
- Sponsor
- Aculys Pharma, Inc.
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in narcolepsy comparing BF2.649 (pitolisant) arm with Placebo arm (2 arms). Primary endpoints: Primary: Safety and tolerability of BF2.649 and Primary: Pharmacokinetics of BF2.649. Started Jan 2022; status: active, not recruiting.
02
Drugs
pitolisant
03
Conditions
narcolepsy
Beyond the preview
Go deeper on jRCT2071210104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210104.